Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli
- Conditions
- Infections
- Registration Number
- NCT00300560
- Lead Sponsor
- Mahidol University
- Brief Summary
In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.
- Detailed Description
In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.The primary outcome is clinical response and secondary outcomes are microbiological response and adverse events.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 152
- Age > 18 yr.
- Hospitalized to Siriraj Hospital
- Infections with ESBL-producing E.coli or K.pneumoniae
- Consent informed consent
- Pregnancy or lactating mother
- Colistin allergy
- Neurologic diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Clinical response
- Secondary Outcome Measures
Name Time Method Microbiological response
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Division of Infectious disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital
🇹🇭Bangkoknoi, Bangkok, Thailand
Division of Infectious disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital🇹🇭Bangkoknoi, Bangkok, ThailandSunee Thanakhumtorn, RNContact662 4197000srstn@mahidol.ac.thVisanu Thamlikitkul, MDPrincipal InvestigatorPornpan Koomanachai, MDSub InvestigatorHutsaya Tantipong, MDSub InvestigatorSriripetcharat Mekviwattanawong, MDSub InvestigatorPasri Maharomn, MDSub InvestigatorPinyo Rattanaumpawan, MDSub Investigator